P1.104. Potential Survival Benefit of Longitudinal ctDNA-Guided Treatment Adaptation in Advanced Esophageal Cancer

Clicks: 3
ID: 325731
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #68 of 453 articles by views in diseases of the esophagus : official journal of the international society for diseases of the esophagus

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 453 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Topic Esophageal Cancer: Management of Metastatic Cancer Background We have developed a tumor-specific circulating tumor DNA (ctDNA) monitoring test using digital PCR, termed the OTS (off-the-shelf)-assay. While recent attention has focused on minimal residual disease detection for early relapse diagnosis and to guide adjuvant therapy decisions, we have emphasized the importance of timely treatment management based on serial ctDNA dynamics. Methods In our previous study of 42 patients with esophageal cancer (EC), the ratio of post- to pre-treatment ctDNA levels after the initial chemotherapy cycle (post/pre-ctDNA) demonstrated strong prognostic value. Patients with post/pre-ctDNA <10% showed better overall survival (OS) than those with ≥10% (HR 0.40; P = 0.031). Furthermore, patients who achieved ctDNA clearance within 90 days of treatment initiation showed markedly improved prognosis compared with those who remained ctDNA-positive (HR 0.10; P < 0.001). Based on these findings, we are conducting a randomized controlled trial (CHANGE study) to evaluate whether ctDNA-guided clinical management can improve outcomes in advanced EC. Results This trial enrolls 85 patients with Stage III/IV EC who received first-line chemotherapy. After assessment of ctDNA dynamics during the first chemotherapy cycle, patients with post/pre-ctDNA ≥10% are randomized to either the conventional arm (Group A, n=15), in which treatment decisions are made by standard clinical assessments, or the ctDNA-guided arm (Group B, n=18), in which treatment strategies are repeatedly adjusted based on serial ctDNA dynamics. The primary endpoint is 2-year OS. In an interim analysis (median follow-up 373 [36-1276] days), Group B showed improved 2-year OS compared with Group A (65.2% vs 26.0%; HR 0.28, 95% CI 0.11–0.75, P = 0.01). Conclusion These preliminary results may suggest that longitudinal personalized ctDNA monitoring with timely treatment adaptation contributes to improved survival outcomes in patients with advanced EC.
Reference Key
openalex_W7203938447 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Takeshi Iwaya, Fumitaka Endo, Ryosuke Fujisawa, Haruka Nikai, Hayato Hiraki, Akiko Yashima‐Abo, Hiroaki Itamochi, 西塚哲
Journal diseases of the esophagus : official journal of the international society for diseases of the esophagus
Year 2026
DOI
10.1093/dote/doag077.252
URL
https://doi.org/10.1093/dote/doag077.252
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.